Nonserious Infections. Should There Be Cause for Serious Concerns?

Kathryn H. Dao, Morley Herbert, Nadia Habal, John J. Cush

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.

Original languageEnglish (US)
Pages (from-to)707-725
Number of pages19
JournalRheumatic Disease Clinics of North America
Volume38
Issue number4
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Infection
Tumor Necrosis Factor-alpha
Urinary Tract Infections
Immunosuppression
Randomized Controlled Trials
Incidence
Etanercept
Adalimumab
Infliximab

Keywords

  • Adalimumab
  • Anti-TNF
  • Etanercept
  • Infliximab
  • Nonserious infections
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Rheumatology

Cite this

Nonserious Infections. Should There Be Cause for Serious Concerns? / Dao, Kathryn H.; Herbert, Morley; Habal, Nadia; Cush, John J.

In: Rheumatic Disease Clinics of North America, Vol. 38, No. 4, 01.11.2012, p. 707-725.

Research output: Contribution to journalReview article

@article{05f4a996f6ef4f71a62c48631b7f5aaa,
title = "Nonserious Infections. Should There Be Cause for Serious Concerns?",
abstract = "Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.",
keywords = "Adalimumab, Anti-TNF, Etanercept, Infliximab, Nonserious infections, Rheumatoid arthritis, Safety",
author = "Dao, {Kathryn H.} and Morley Herbert and Nadia Habal and Cush, {John J.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.rdc.2012.08.016",
language = "English (US)",
volume = "38",
pages = "707--725",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Nonserious Infections. Should There Be Cause for Serious Concerns?

AU - Dao, Kathryn H.

AU - Herbert, Morley

AU - Habal, Nadia

AU - Cush, John J.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.

AB - Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.

KW - Adalimumab

KW - Anti-TNF

KW - Etanercept

KW - Infliximab

KW - Nonserious infections

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84868357446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868357446&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2012.08.016

DO - 10.1016/j.rdc.2012.08.016

M3 - Review article

C2 - 23137578

AN - SCOPUS:84868357446

VL - 38

SP - 707

EP - 725

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 4

ER -